Loading stock data…
Dianthus Therapeutics, Inc. (DNTH)
$95.68+0.33 (+0.35%)
After Hours$94.37-1.31 (-1.37%)· Last close Jun 29
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dianthus Therapeutics, Inc. in the Healthcare sector is trading at $95.68 with a market capitalization of $4.6B. Wall Street consensus targets $127.67 (12 analysts), implying a +33.4% move over the next 12 months. The stock is currently near its 52-week high of $97.38, remaining 61.3% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +33.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $463,000↑ | $284,000↓ | $396,000↑ | $193,000↓ | $1.16M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$46.53M↑ | -$69.54M↓ | -$40.29M↓ | -$34.93M↓ | -$33.18M |
| Net Income | -$40.83M↑ | -$64.43M↓ | -$36.77M↓ | -$31.63M↓ | -$29.51M |
Peer Comparison
JNJUNHPFE
Fundamentals
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.46%
Volume
Today's trading volume
1.35M
Recent News
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger
Dianthus Therapeutics reported a 75% response rate in a late-stage trial of claseprubart in CIDP. The update comes shortly after Sanofi discontinued a similar CIDP trial, leaving fewer competitors in this space. The new data arrive with Dianthus Therapeutics (NasdaqCM:DNTH) shares at $82.07. Dianthus Therapeutics, trading under NasdaqCM:DNTH, is drawing attention after reporting late-stage data for claseprubart in CIDP, with a 75% response rate. The company enters this news with the stock...
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results
In the first part of the CIDP study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said.
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
Sanofi scrapped a final-phase study Wednesday of an experimental CIDP treatment. The stock tumbled in response.
Stocks Settle Sharply Lower on Escalating Middle East Tensions
The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June E-mini S&P futures (ESM26 ) fell -1.62%, and June E-mini Nasdaq futures...